Class A to D Risk Classification in Myanmar

1. Key takeaways

Medical device classification in Myanmar adopts the four-tier risk framework of the AMDD and does not use Roman numeral or ordinal classification. The four classes are: Class A (low risk), Class B (low to moderate risk), Class C (moderate to high risk) and Class D (high risk).

• Chinese-language channels widely circulate the Class I, Class II and Class III formulation, which transplants the system of China’s Regulation on the Supervision and Administration of Medical Devices onto Myanmar and does not match the actual practice of the Myanmar FDA. This content set uses the Class A, B, C and D formulation consistently across the whole site.
• The source of the classification is Section 2, Classification of Medical Device, of the Technical Guideline for Online Submission of Medical Devices of the Myanmar FDA.
• The risk classification rules are divided into two sets: one for medical devices other than IVD medical devices and one for IVD medical devices.
• For non-invasive devices, general device rules 1 to 4 address contact with injured skin; conveyance or storage of body fluids, tissues, liquids or gases; modification of the composition of blood or other body liquids; and other non-invasive devices.
• For invasive devices, general device rules from rule 5 onwards address, among other things, devices that invade body orifices by non-surgical invasion.
• The technical framework for the whole classification system is the ASEAN Medical Device Directive (AMDD, 2015), so determinations made under other AMDD-based markets can serve as supporting references while the Myanmar guideline remains the operative source. Reusing such determinations is a practical estimate pending verification against the FDA’s current review practice.

2. Legal basis

The table below consolidates the classification framework. Because classification determines the depth of documentation and the intensity of review, each row should be read as an input to the class determination rather than as an isolated statement.

3. Expert insights

Insight 1: the class determines documentation depth, review intensity and subsequent obligations. Once the class is fixed, the preparation workload in technical documentation, clinical evidence and quality system evidence is fixed with it. Misclassification is the primary cause of deficiency loops and timeline extension: over-classifying wastes resources, while under-classifying leads directly to rejection.

Insight 2: the four non-invasive rules form a progressive judgement chain. Rule 1 is layered by wound depth and healing mode: devices used solely as a mechanical barrier, for compression or for absorption of exudates are Class A; devices used on wounds that have breached the dermis are Class B; devices used on chronic ulcerated wounds that can only heal by secondary intention are Class C. In self-assessment, companies must determine the wound type first, then the class.

Insight 3: rule 2 uses connection to other devices and involvement of blood as escalation conditions. Dressing packs for gravity infusion alone are Class A; devices that may be connected to Class B or higher active devices are Class B; devices used for conveying blood or for storing organs are Class B; blood bags are Class C. This rule is a frequent point of dispute for consumable products.

Insight 4: rule 3 distinguishes by processing mode rather than by product form. Devices that alter the composition of blood or other body liquids are Class C; devices that only filter, centrifuge, or exchange gases or heat are Class B. Dialysate falling into Class C and particulate filters for extracorporeal circulation falling into Class B are the results of applying this rule.

Insight 5: IVDs follow a separate set of rules and must be assessed separately. When preparing IVD products, companies should expressly cite the IVD classification rules rather than the general device rules. Which borderline products fall into which rule set remains a practical estimate pending verification against the FDA’s current review practice.

4. Practical recommendations

• Complete the classification self-assessment and record the reasoning in writing before preparing the dossier. The classification conclusion should serve as the first document of the dossier.
• Apply rules 1 and 2 with focus to consumable products. Check wound type and connection mode item by item.
• Apply the separate IVD classification rules to IVD products. Do not apply the general device rules by analogy.
• Where the classification is uncertain, confirm with the FDA through the local authorised representative. Rely on the written interpretation.
• Synchronise the classification conclusion to labelling, instructions for use and import documents. Keep the whole chain consistent.

5. Verification checklist

• □ Confirmed that Myanmar adopts the Class A, B, C and D classification
• □ Confirmed that the Class I, Class II and Class III formulation is not used
• □ Completed the classification self-assessment and recorded the reasoning in writing
• □ Checked rules 1 and 2 for consumable products
• □ Applied the separate classification rules to IVD products
• □ Obtained written FDA confirmation where the classification was uncertain
• □ Synchronised the classification conclusion to labelling and import documents

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com